Daily Ards Research Analysis

Acute respiratory distress syndrome (ARDS), a severe condition associated with high mortality, is characterized by uncontrollable inflammation and oxidative stress linked to mitochondrial dysfunction. Dynamin-related protein 1 (Drp1) drives pathological mitochondrial fission in patients with ARDS, leading to a sustained inflammatory response and excessive mitochondrial reactive oxygen species (mtROS) production. However, the specific inhibition of Drp1 in lung mitochondria remains challenging. Here, a multifunctional nanocomposite (DTP-LSA@MTC NPs) was developed by integrating the Drp1 inhibitor Mdivi-1 with a mitochondria-targeting tannic acid-cerium (TA-Ce) nanozyme network. Additionally, surface functionalization with an LSA peptide enabled specific binding to DPEP1 on the inflamed pulmonary endothelium, enhancing site-specific accumulation and competitively inhibiting neutrophil recruitment. Following intravenous administration, these nanoparticles efficiently targeted both pulmonary microvascular endothelial cells and mitochondria, suppressed the activity of the Drp1-NLRP3 inflammasome axis, and scavenged ROS, ultimately preventing the development of cytokine storms in preclinical models of ARDS. This targeted nanotherapeutic strategy offers a potent and translatable approach for treating ARDS and related inflammatory disorders.

PURPOSE: Sixty years after its initial description, the epidemiology and pathophysiology of acute respiratory distress syndrome (ARDS) have evolved substantially. This narrative review examines whether ARDS is a preventable disease, evaluating the evidence for successful prevention of iatrogenic phenotypes and the challenges that remain for noniatrogenic causes. METHODS: We reviewed the published literature on ARDS prevention, including evidence from clinical trials, population-based epidemiologic studies, implementation research, and biological subphenotyping studies, synthesized through the framework of the multiple hit hypothesis. RESULTS: For iatrogenic phenotypes, ARDS prevention has substantially succeeded. Transfusion-related acute lung injury has declined dramatically following male-predominant plasma policies. Lung-protective ventilation initiated in emergency departments and operating rooms has reduced both ARDS incidence and mortality. Bundled care approaches combining restrictive fluid and transfusion strategies, aspiration precautions, and early antimicrobials have further reduced iatrogenic lung injury. What remains under the ARDS label is an increasingly heterogeneous collection of conditions driven by upstream host-pathogen interactions and biological phenotype. Pharmacologic prevention trials in unselected populations have been consistently disappointing, likely because biologically distinct subphenotypes respond differently to treatment. Additionally, the population-attributable fraction of death from ARDS is modest, suggesting that even successful prevention may not translate into proportional mortality reduction. CONCLUSION: Extending prevention beyond iatrogenic causes will require precision approaches: phenotype-targeted pharmacotherapy, individualized mechanical ventilation, and systematic implementation of evidence-based practices across the care continuum.

PURPOSE: While acute brain dysfunction (ABD, i.e., delirium and coma) is associated with significantly increased morbidity in critically ill patients, it presents with great heterogeneity that poses a challenge for management and prognostication. While machine learning may be promising for subgroup identification, this approach has not yet been applied to COVID-19 patients with ABD. The aim of our study was to identify distinct clusters among critically ill patients with COVID-19 based on ICU admission data and evaluate their association with clinical outcomes. METHODS: We retrospectively analyzed an international multicenter database (COVID-D study) of critically ill adult patients with COVID-19 during the first pandemic wave and ABD using clinical features on day 1 of admission as input variables. We applied unsupervised machine learning in a pilot attempt to discover clusters of ABD patients. Hierarchical clustering was performed with a bootstrap-based robustness assessment after dimensionality reduction. Clusters were analyzed for differences in neurological outcomes, mechanical ventilation, and survival. RESULTS: We analyzed 1,631 critically ill COVID-19 patients with ABD, identifying four reproducible clusters with distinct clinical and neurological profiles. Cluster 1 ("mild respiratory failure," n = 335) had the most favorable outcomes, with the shortest duration of delirium (4.13 days) and mechanical ventilation. Cluster 2 ("moderate ARDS," n = 508) showed a comparable delirium incidence but the longest duration (5.18 days). Cluster 3 ("early severe ARDS," n = 161) included patients who underwent prone positioning and mechanical ventilation early from the day of admission, with higher rates of coma (100%), including persistent coma (27.3%). Cluster 4 ("late severe ARDS," n = 475) represented severely ill patients with the longest coma duration (11.2 days) and the lowest delirium-free and coma-free (DFCF) days (4.74), in relation to deep and prolonged sedation. Despite the wide range of ABD durations across four groups, no significantly different 28-day mortality (23.6-38.0, p > 0.78), ICU (15.8-19.2 days range, p = 0.154) and hospital (22.5-26.7 days range, p = 0.259) length of stay were observed among clusters. CONCLUSION: This pilot analysis of ICU admission data from the first COVID-19 wave suggests the existence of clinically distinct clusters among patients with acute brain dysfunction. Differences were observed in the type and duration of delirium and coma, though these did not translate into differences in 28-day survival. This exploratory work may support targeted delirium prevention strategies, but prospective studies are required to determine its clinical utility in modern ICU settings.